Publications
Access Travere’s peer-reviewed publications.
Results 45
Sort by
Practical Considerations for the Use of Sparsentan in the Treatment of Patients with IgAN in Clinical Practice
The Humanistic Burden of Focal Segmental Glomerulosclerosis on Patients and Care‑Partners in the United States
Dual Inhibition of the Endothelin and Angiotensin Receptor Ameliorates Renal and Inner Ear Pathologies in Alport Mice
Efficacy and Safety of ACE Inhibitor and Angiotensin Receptor Blocker Therapies in Primary Focal Segmental Glomerulosclerosis Treatment: A Systematic Review and Meta-Analysis
Differentiating Primary and Secondary FSGS Using Non-Invasive Urine Biomarkers
Clinical Characteristics and Histopathology in Adults With Focal Segmental Glomerulosclerosis
Population Pharmacokinetic Analysis of Sparsentan in Healthy Volunteers and Patients with Focal Segmental Glomerulosclerosis
Estimation of Health State Utility Values for Immunoglobulin A Nephropathy: A Time Trade-Off Analysis
Sparsentan Clinical Trials in Glomerular Diseases: Defining Endpoints and a Path Forward in Light of the Parasol Initiative
The Dual Endothelin A and Angiotensin II Type 1 Receptor Antagonist Sparsentan (FILSPARI®) Exhibits a Safe Nonclinical Male Fertility Toxicity Profile
Epidemiology and Burden of Focal Segmental Glomerulosclerosis Among United States Veterans: An Analysis of Veteran’s Affairs Data
Assessment of Health‐Related Quality of Life in Patients With Cystinuria on Tiopronin Therapy